Advertisement

Chemotherapy of Addiction — A Pharmacological Perspective

  • Donald R. Jasinski

Abstract

Accompanying the greater use of drugs to treat narcotic addicts has been the development of new drugs for such treatment. It is conceivable that in the near future the therapist will choose from an array of drugs to treat addict patients. Such a situation would be analogous to that with the chemotherapy of infectious diseases. In such a situation, knowledge of the comparative pharmacology of the available drugs is one factor necessary for rational therapy. This presentation will review the pharmacology of the narcotic antagonists in relation to each other and in relation to those narcotic analgesics used as maintenance drugs. This presentation will not review the relative efficacies of the various classes of agents used to treat addicts nor the rationales for choosing among the agents.

Keywords

Partial Agonist Physical Dependence Agonist Effect Narcotic Analgesic Addiction Research 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fraser, H.F. and Isbell, H. 1952. Actions and addiction liabilities of alpha-acetylmethadols in man. J. Pharmacol. Exp. Ther. 105: 458–465.Google Scholar
  2. Jasinski, D.R. 1977. Assessment of the abuse potentiality of mor-Google Scholar
  3. phine-like drugs. In: Drug Addiction. I. Morphine, Sedative-Hypnotic and Alcohol Dependence. Handbook of Experimental Pharmacology. Vol. 45, W.R. Martin (ed.), pp. 197–258. Berlin-Heidelberg-New York: Springer-Verlag.Google Scholar
  4. Jasinski, D.R., Pevnick, J.S., and Griffith, J.D. 1978. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiciton. Arch. Gen. Psychiatry. 35: 501–516.CrossRefGoogle Scholar
  5. Martin, W.R., Fraser, H.F., Gorodetzky, C.W., and Rosenberg, D.E. 1965. Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2’-hydroxy-5,9-dimethyl-6, 7-benzomorphan (cyclazocine, Win 20–740; ARC II-C-3). J. Pharmacol. Exp. Ther. 150: 426–436.Google Scholar
  6. Martin, W.R., Gorodetzky, C.W., and McClane, T.K. 1966. An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. Ther. 7: 455–465.Google Scholar
  7. Martin, W.R., Jasinski, D.R., Haertzen, C.A., Kay, D.C., Jones, B.E., Mansky, P.A., and Carpenter, R.W. 1973a. Methadone-a reevaluation. Arch. Gen. Psychiatry. 28: 286–295.CrossRefGoogle Scholar
  8. Martin, W.R., Jasinski, D.R., and Mansky, P.A. 1973b. Naltrexone, an antagonist for the treatment of heroin dependence. Arch. Gen. Psychiatry. 28: 784–791.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • Donald R. Jasinski
    • 1
  1. 1.Addiction Research CenterNational Institute on Drug AbuseUSA

Personalised recommendations